98%
921
2 minutes
20
Although subdural drain (SDD) placement reduces recurrence after burr-hole surgery for chronic subdural hematoma (CSDH), complications have led our institution to discontinue its routine use. During the first year following this change, the recurrence rate was 14.6%, comparable to the recurrence rate observed prior to discontinuation. Therefore, we retrospectively compared 150 cases with SDD (SDD+ group) and 129 recent cases without SDD (SDD- group). Patient characteristics, recurrence rates, complications, operative time, hospital stay, and costs were analyzed. Recurrence occurred in 13.9% of the SDD+ group and 8.0% of the SDD- group (p = 0.119). Post-hoc analysis revealed low statistical power (34.1%), suggesting a risk of Type II error. The SDD- group had significantly shorter operative time (40.9 vs. 54.9 minutes) and hospital stay (6.0 vs. 11.8 days), with a cost reduction of $811.8 per case. Complication rates were similar (4% vs. 1%), but three serious SDD-related complications were noted in the SDD+ group. Multivariate analysis identified preoperative hematoma thickness and postoperative subdural thickness as independent recurrence factors, while SDD use was not. In conclusion, omitting SDD placement did not significantly increase recurrence but was associated with shorter operative times, reduced hospital stays and costs, and fewer serious complications. While the study may be underpowered to definitively rule out a difference in recurrence, these findings support the feasibility of omitting SDD in initial surgeries. Future randomized controlled trials are warranted to confirm these results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2025.124431 | DOI Listing |
World Neurosurg
September 2025
Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:
Although subdural drain (SDD) placement reduces recurrence after burr-hole surgery for chronic subdural hematoma (CSDH), complications have led our institution to discontinue its routine use. During the first year following this change, the recurrence rate was 14.6%, comparable to the recurrence rate observed prior to discontinuation.
View Article and Find Full Text PDFJ Pediatr Surg
September 2025
Department of Pediatric Surgery, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States.
Introduction: Pectus excavatum is surgically managed with minimally invasive bar placement. Pain control effectively determines the postoperative length of stay (LOS). Pain management after this operation has been transformed with the use of intercostal cryoablation, with LOS of one night being a previous standard of care.
View Article and Find Full Text PDFJ Shoulder Elbow Surg
August 2025
: Department of Orthopedic Surgery, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA. Electronic address:
Introduction: Cost conservation and value are major components of orthopedic surgery and health economics. One measure frequently used by surgeons to mitigate cost is the utilization of same day discharge (SDD) after total shoulder arthroplasty (TSA). With SDD we must also identify patient factors that support its safety and suitability.
View Article and Find Full Text PDFArthroplast Today
August 2025
Anderson Orthopaedic Research Institute, Alexandria, VA, USA.
Background: Over 35% of the US population is obese, leading to earlier arthroplasty needs, increased comorbidities, surgical challenges, and higher complication and revision rates. Concurrently, outpatient hip and knee arthroplasty procedures are increasing. This study aimed to evaluate early complication rates of same-day discharge (SDD) arthroplasty in severely obese patients (body mass index [BMI] ≥40).
View Article and Find Full Text PDFMol Pharm
August 2025
Institute of Pharmacy, Faculty I of Natural Sciences, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Strasse 3, Halle (Saale) 06120, Germany.
Proteolysis targeting chimeras (PROTACs) are heterobifunctional degraders with a unique mode of action that permits access to "undruggable" targets. These molecules pose challenges in terms of solubility and bioavailability due to their physicochemical properties. So far, very little information is available on the potential of enabling formulations of PROTACs in pharmacokinetic studies.
View Article and Find Full Text PDF